Assessing the unmet treatment need in partial‐onset epilepsy: Looking beyond seizure control

Summary Patients with resistant epilepsy are often coprescribed multiple medications and are more likely to experience drug–drug interactions and adverse events (AEs). A new generation of antiepileptic drugs (AEDs) has been developed with improved safety/tolerability profiles. To evaluate the unmet treatment needs in epilepsy, a comprehensive search of the English‐language literature was conducted on Medline and other databases using the terms “partial epilepsy” and “focal seizure,” focusing on newer AEDs. Sixty‐nine articles were identified. Most patients experienced AEs, which were generally mild–moderate in severity. Drug–drug interactions existed for 6 of 11 AEDs for which data were available. There is evidence for depressive symptoms being associated with zonisamide, and mood‐stabilizing effects were shown for lamotrigine and pregabalin. Levetiracetam and eslicarbazepine improved cognitive function. Vigabatrin may increase the risk of developing psychosis. Health‐related quality of life (HRQoL) was inversely correlated with seizure frequency. Discontinuation rates were often high, although treatment retention improved with slower dose titration. Adjunctive therapy with newer AEDs has the potential to enhance HRQoL and treatment continuation in patients with partial epilepsy. There remains room for improvement in the management of epilepsy, and better treatments and longer‐term trials are needed to meet the special requirements of refractory patients.